Pipeline & Platform
Using proprietary particle science and manufacturing technology, Pearl is developing a broad portfolio of products in the metered dose inhaler (MDI) format for the treatment of prevalent chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma and rhinosinusitis. MDIs are the most widely used drug delivery format for inhaled treatments for respiratory diseases. Yet, major therapies, particularly dual and triple combinations of well-known inhaled medicines, have proven to be difficult to develop in MDI format due to formulation challenges such as inconsistent dosing, instability over time, and partial or variable delivery to the airways.
Pearl Proprietary Particles
Pearl's scientists and engineers have addressed fundamental chemistry, manufacturing and control (CMC) issues associated with MDIs by advancing a proprietary formulation technology that uses lipid-based porous particles to create stable cosuspensions with drug crystals in HFA propellants, and high performance aerosols upon actuation. This technology is suitable for formulating monotherapy and combination products as the porous particles enable efficient targeting and distribution of drug to the lungs. Pearl’s cosuspension technology does not employ any special additives such as cosolvents (ethanol), or other suspension modifying agents.